+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bifidobacterium Longum Subsp. Infantis M-63 Market by Application, Form, End User, Distribution Channel - Global Forecast to 2030- Product Image
Bifidobacterium Longum Subsp. Infantis M-63 Market by Application, Form, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Bifidobacterium Longum Subsp. Infantis M-63 Market by Application, Form, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082211
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Introducing a Breakthrough in Infant Microbiome Health

Bifidobacterium longum subsp. infantis M-63 has emerged as a beacon of innovation within the probiotic landscape, distinguished by its remarkable ability to colonize the infant gut and modulate immune development. This executive summary presents a focused exploration of the factors shaping its market trajectory, offering a succinct yet comprehensive lens through which industry leaders can assess opportunities and challenges. We begin by contextualizing the strain’s unique attributes, tracing its discovery, clinical validation, and commercial adoption. By synthesizing recent clinical trials, regulatory milestones, and formulation breakthroughs, this report underscores the scientific rigor supporting M-63’s safety and efficacy profile. Transitional insights highlight how evolving consumer demands and heightened regulatory scrutiny have converged to position this strain as a preferred candidate for infant nutrition and beyond.

Adopting an evidence-based approach, the introduction sets the tone for a deeper dive into market dynamics without presupposing growth metrics. Instead, it emphasizes the critical inflection points driving stakeholder engagement-from pediatricians and dietitians to manufacturers and investors. As the formal gateway into subsequent analyses, this section ensures decision-makers grasp the foundational science and market relevance of M-63 before unpacking tariff implications, segmentation frameworks, regional trends, competitive behaviors, and strategic imperatives.

Evolutionary Forces Shaping the Probiotic Market Landscape

The probiotic arena is witnessing a convergence of scientific advancements, shifting consumer preferences, and technological innovations, collectively redefining the market landscape. Precision formulations leveraging next-generation sequencing have enabled targeted delivery of Bifidobacterium longum subsp. infantis M-63, heightening its competitive edge in infant formulas and therapeutic supplements. Moreover, the growing emphasis on gut-brain axis research has propelled investor confidence, fostering cross-sector partnerships that span biotech start-ups and established consumer health conglomerates.

Simultaneously, sustainability considerations are driving manufacturers toward eco-friendly fermentation processes, aligning product narratives with broader environmental, social, and governance (ESG) imperatives. This shift not only enhances brand authenticity but also unlocks new distribution models where traceability and transparency are paramount. Furthermore, digital health tools and direct-to-consumer platforms have democratized access, enabling personalized probiotic regimens informed by consumer-generated health data. Together, these transformative forces underscore a market that is increasingly interconnected, data-driven, and purpose-oriented, with M-63 poised to capitalize on its validated health benefits and versatility across diverse applications.

Unpacking the Effects of New U.S. Tariff Measures

The recent enactment of United States tariff adjustments in 2025 has introduced noteworthy complexities to the global probiotic supply chain, affecting raw material sourcing and end-product pricing. Key intermediates imported from select Asian biotechnology hubs are now subject to revised duties, prompting manufacturers to reassess supplier portfolios and logistics routes. In response, some producers have accelerated nearshoring initiatives, relocating fermentation facilities closer to final markets to circumvent elevated import costs.

Meanwhile, domestic ingredient producers are seizing the opportunity to expand capacity, while negotiators pursue exemptions for probiotic strains with recognized health credentials. This dynamic has fostered a duality wherein cost pressures coexist with strategic investments in local infrastructure. Industry stakeholders are actively engaging in policy dialogues to mitigate long-term disruptions, advocating for harmonized standards that ensure both economic resilience and uninterrupted patient access. Thus, while the tariff landscape introduces headwinds, it also catalyzes supply chain diversification and reinforces the strategic value of vertically integrated operations.

Decoding Market Segmentation for Strategic Growth

A nuanced understanding of application niches is essential for stakeholders seeking to harness the diverse potential of Bifidobacterium longum subsp. infantis M-63. In animal feed, opportunities span aquaculture feed, livestock feed, and pet food, with each subcategory demanding tailored stability profiles and dosage forms to optimize gut health across species. Dietary supplements encompass adult, elderly, and infant formulations, where consumer education and dosage precision distinguish leading products. In the functional foods arena, manufacturers integrate M-63 into beverages, dairy offerings, and snack bars, blending efficacy with sensory appeal. Infant formula developers navigate cow milk-based, hypoallergenic, and soy-based variants, each requiring rigorous compatibility testing to preserve strain viability. Pharmaceutical innovators, meanwhile, explore adjunctive therapies that augment standard treatments and novel probiotic therapeutics designed for specific indications.

Form selection further refines market positioning: enteric-coated and non-enteric capsules deliver precision dosing, while liquids and powders offer flexibility for customized regimens. Tablets cater to adult users seeking convenience, particularly in outpatient settings. End-user distinctions among adults, children, elderly, and infants guide tailored messaging and regulatory compliance. Distribution channels span direct marketing through healthcare practitioners, e-commerce platforms both direct-to-consumer and third-party, private and public hospital procurement, as well as chain and independent pharmacies. Each channel demands a unique value proposition, whether it’s clinician endorsement, digital engagement, institutional contracting, or retail accessibility. Synthesizing these layers enables targeted strategies that resonate with distinct customer segments while maximizing M-63’s market footprint.

Regional Dynamics Driving Global Adoption Trends

Regional insights illuminate how macroeconomic conditions, healthcare infrastructure, and cultural attitudes shape the adoption of Bifidobacterium longum subsp. infantis M-63. In the Americas, robust investment in pediatric nutrition research and accessible insurance frameworks bolster demand in both infant formula and therapeutic applications. Manufacturers leverage well-established distribution networks, while direct-to-consumer digital platforms gain traction among health-savvy parents. Europe, the Middle East, and Africa exhibit diverse regulatory landscapes, where stringent European safety standards coexist with rapidly growing markets in the Gulf and North Africa. Local partnerships and adaptive formulations are key to navigating this complexity, as stakeholders must balance compliance with nimble go-to-market strategies. The Asia-Pacific region stands out for its investment in R&D infrastructure and a burgeoning middle-class consumer base prioritizing preventive health. Collaboration between academic institutions and industry players accelerates product innovation, while omnichannel retail ecosystems facilitate widespread access. Understanding these distinct regional dynamics empowers decision-makers to tailor market entry and expansion plans, ensuring alignment with local drivers and barriers.

Competitive Landscape and Strategic Initiatives

The competitive landscape for Bifidobacterium longum subsp. infantis M-63 features a blend of established life sciences conglomerates and agile biotechnology firms. Key players have differentiated through proprietary strain development, fortified by patent portfolios that span fermentation processes and delivery technologies. Some organizations prioritize strategic partnerships with academic centers to co-develop clinical evidence and boost market credibility. Others focus on vertical integration, securing upstream feedstock and downstream manufacturing capabilities to enhance cost efficiencies and quality control. Collaborative alliances between probiotic specialists and digital health innovators have emerged, yielding platforms for personalized microbiome assessments and subscription-based delivery models. In parallel, investment activity underscores the sector’s growth potential: venture capital rounds and strategic acquisitions have fueled capacity expansions and entry into new therapeutic domains. By monitoring competitor trajectories-ranging from pipeline progress to go-to-market pivots-industry leaders can anticipate market shifts and identify partnership or acquisition targets that complement their strategic vision.

Strategic Imperatives for Market Leadership

Industry leaders poised to capitalize on M-63’s promise should prioritize a multifaceted approach that integrates innovation, operational agility, and stakeholder engagement. First, investing in robust clinical research programs will solidify the strain’s therapeutic positioning, enabling differentiation in a crowded marketplace. Concurrently, optimizing manufacturing processes through advanced bioreactor systems and continuous fermentation techniques can drive down production costs and improve scalability. Next, forging strategic alliances with pediatric healthcare networks and patient advocacy groups will amplify product credibility and facilitate educational campaigns. In parallel, adopting a modular distribution strategy that leverages both digital channels and select institutional partnerships will enhance market reach while retaining flexibility. Finally, embedding sustainability metrics into every aspect of the value chain-from raw material sourcing to packaging-will resonate with increasingly conscious consumers and regulators alike. By executing these recommendations in concert, organizations can secure first-mover advantages and sustainable growth trajectories in the dynamic M-63 ecosystem.

Rigorous Framework Underpinning the Research

This study employs a rigorous, multi-tiered methodology designed to deliver comprehensive and reliable insights. Primary research initiatives included structured interviews with pediatric gastroenterologists, formulation scientists, and procurement officers, complemented by roundtables with regulatory experts across key jurisdictions. Secondary research encompassed a thorough review of peer-reviewed journals, clinical trial registries, patent filings, and industry whitepapers. Market dynamics were further validated through proprietary databases tracking import/export flows, investment activity, and distribution channel performance. Data triangulation techniques ensured consistency across varied sources, while sensitivity analyses tested the robustness of qualitative conclusions. The segmentation framework was constructed iteratively, integrating application, form, end-user, and channel dimensions to reflect real-world purchasing behaviors. Quality assurance processes included peer reviews by subject matter experts and final audits to verify accuracy and clarity. This methodological rigor underpins the credibility of the strategic narratives and recommendations presented herein.

Synthesizing Insights and Future Outlook

The multifaceted analysis presented in this executive summary underscores the transformative potential of Bifidobacterium longum subsp. infantis M-63 within infant nutrition and beyond. From shifting supply chain paradigms influenced by tariff policies to granular insights on segmentation and regional dynamics, the report offers a panoramic view of the forces shaping market evolution. Competitive intelligence highlights both established players and emerging disruptors, while actionable recommendations chart a clear path for securing leadership. Altogether, these distilled findings equip stakeholders with the strategic clarity needed to navigate complexity and seize opportunities at every link of the value chain. As the probiotic sector continues to mature, the confluence of clinical validation, operational excellence, and purpose-driven narratives will determine which market participants rise to prominence.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Animal Feed
      • Aquaculture Feed
      • Livestock Feed
      • Pet Food
    • Dietary Supplements
      • Adult Supplements
      • Elderly Supplements
      • Infant Supplements
    • Functional Foods
      • Beverages
      • Dairy Products
      • Snack Bars
    • Infant Formula
      • Cow Milk-Based
      • Hypoallergenic
      • Soy-Based
    • Pharmaceuticals
      • Adjunctive Therapies
      • Probiotic Therapeutics
  • Form
    • Capsule
      • Enteric-Coated
      • Non-Enteric
    • Liquid
    • Powder
    • Tablet
  • End User
    • Adults
    • Children
    • Elderly
    • Infants
  • Distribution Channel
    • Direct Sales
      • Direct Marketing
      • Healthcare Practitioner Channel
    • E-Commerce
      • Direct-To-Consumer
      • Third-Party Platform
    • Hospitals
      • Private Hospital
      • Public Hospital
    • Retail Pharmacies
      • Chain Pharmacy
      • Independent Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Morinaga Milk Industry Co., Ltd.
  • Danone S.A.
  • Yakult Honsha Co., Ltd.
  • Nestlé S.A.
  • Chr. Hansen A/S
  • DuPont de Nemours, Inc.
  • Kerry Group plc
  • Lallemand Inc.
  • BioGaia AB
  • Probi AB

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Application
8.1. Introduction
8.2. Animal Feed
8.2.1. Aquaculture Feed
8.2.2. Livestock Feed
8.2.3. Pet Food
8.3. Dietary Supplements
8.3.1. Adult Supplements
8.3.2. Elderly Supplements
8.3.3. Infant Supplements
8.4. Functional Foods
8.4.1. Beverages
8.4.2. Dairy Products
8.4.3. Snack Bars
8.5. Infant Formula
8.5.1. Cow Milk-Based
8.5.2. Hypoallergenic
8.5.3. Soy-Based
8.6. Pharmaceuticals
8.6.1. Adjunctive Therapies
8.6.2. Probiotic Therapeutics
9. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Form
9.1. Introduction
9.2. Capsule
9.2.1. Enteric-Coated
9.2.2. Non-Enteric
9.3. Liquid
9.4. Powder
9.5. Tablet
10. Bifidobacterium Longum Subsp. Infantis M-63 Market, by End User
10.1. Introduction
10.2. Adults
10.3. Children
10.4. Elderly
10.5. Infants
11. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.2.1. Direct Marketing
11.2.2. Healthcare Practitioner Channel
11.3. E-Commerce
11.3.1. Direct-To-Consumer
11.3.2. Third-Party Platform
11.4. Hospitals
11.4.1. Private Hospital
11.4.2. Public Hospital
11.5. Retail Pharmacies
11.5.1. Chain Pharmacy
11.5.2. Independent Pharmacy
12. Americas Bifidobacterium Longum Subsp. Infantis M-63 Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Bifidobacterium Longum Subsp. Infantis M-63 Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Morinaga Milk Industry Co., Ltd.
15.3.2. Danone S.A.
15.3.3. Yakult Honsha Co., Ltd.
15.3.4. Nestlé S.A.
15.3.5. Chr. Hansen A/S
15.3.6. DuPont de Nemours, Inc.
15.3.7. Kerry Group plc
15.3.8. Lallemand Inc.
15.3.9. BioGaia AB
15.3.10. Probi AB
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET MULTI-CURRENCY
FIGURE 2. BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET MULTI-LANGUAGE
FIGURE 3. BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY AQUACULTURE FEED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PET FOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULT SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DAIRY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SNACK BARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COW MILK-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HYPOALLERGENIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SOY-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PROBIOTIC THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ENTERIC-COATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY NON-ENTERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT MARKETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HEALTHCARE PRACTITIONER CHANNEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 96. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 97. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 98. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 99. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 102. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 103. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 104. CANADA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 116. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 176. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 178. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 187. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 188. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 190. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 192. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 195. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 196. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 197. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 198. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 201. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 202. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 218. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 220. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 221. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 222. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 223. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 224. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 225. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 226. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 229. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 230. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. ITALY BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 234. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 236. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 237. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 238. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 239. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 240. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 243. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 244. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 245. SPAIN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HOSPITALS, 2018-2030 (

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Bifidobacterium Longum Subsp. Infantis M-63 market report include:
  • Morinaga Milk Industry Co., Ltd.
  • Danone S.A.
  • Yakult Honsha Co., Ltd.
  • Nestlé S.A.
  • Chr. Hansen A/S
  • DuPont de Nemours, Inc.
  • Kerry Group plc
  • Lallemand Inc.
  • BioGaia AB
  • Probi AB

Related Topics

Related Reports

Bifidobacterium Longum Lysate (CAS 96507-89-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Bifidobacterium Longum Lysate (CAS 96507-89-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Longum Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Longum Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 78 Pages
  • Global
From
Immune Health Supplements Market by Distribution Channel, Form, Ingredient - Global Forecast to 2030 - Product Image

Immune Health Supplements Market by Distribution Channel, Form, Ingredient - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
OTC Probiotics Supplement Market - Forecasts from 2025 to 2030 - Product Image

OTC Probiotics Supplement Market - Forecasts from 2025 to 2030

  • Report
  • 148 Pages
  • Global
From
Probiotics Dietary Supplements Market by Product, Strain, Formulation, Distribution Channel, Application, End-user - Global Forecast to 2030 - Product Image

Probiotics Dietary Supplements Market by Product, Strain, Formulation, Distribution Channel, Application, End-user - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.